DK1267909T3 - Fremgangsmåder til blokering af vævsdestruktion ved autoreaktive T-celler - Google Patents

Fremgangsmåder til blokering af vævsdestruktion ved autoreaktive T-celler

Info

Publication number
DK1267909T3
DK1267909T3 DK01933358.2T DK01933358T DK1267909T3 DK 1267909 T3 DK1267909 T3 DK 1267909T3 DK 01933358 T DK01933358 T DK 01933358T DK 1267909 T3 DK1267909 T3 DK 1267909T3
Authority
DK
Denmark
Prior art keywords
cells
methods
autoreactive
polypeptide
purified
Prior art date
Application number
DK01933358.2T
Other languages
English (en)
Inventor
Yang Liu
Pan Zheng
Xue-Feng Bai
Original Assignee
Univ Ohio State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ohio State Res Found filed Critical Univ Ohio State Res Found
Application granted granted Critical
Publication of DK1267909T3 publication Critical patent/DK1267909T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
DK01933358.2T 2000-03-29 2001-03-29 Fremgangsmåder til blokering af vævsdestruktion ved autoreaktive T-celler DK1267909T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19281400P 2000-03-29 2000-03-29
PCT/US2001/040390 WO2001072325A1 (en) 2000-03-29 2001-03-29 Methods of blocking tissue destruction by autoreactive t cells

Publications (1)

Publication Number Publication Date
DK1267909T3 true DK1267909T3 (da) 2010-11-08

Family

ID=22711138

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01933358.2T DK1267909T3 (da) 2000-03-29 2001-03-29 Fremgangsmåder til blokering af vævsdestruktion ved autoreaktive T-celler

Country Status (8)

Country Link
EP (1) EP1267909B1 (da)
JP (1) JP2004500110A (da)
AT (1) ATE475428T1 (da)
AU (2) AU2001259792B2 (da)
CA (1) CA2404340C (da)
DE (1) DE60142684D1 (da)
DK (1) DK1267909T3 (da)
WO (1) WO2001072325A1 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030106084A1 (en) 2000-03-29 2003-06-05 Yang Liu Methods of blocking tissue destruction by autoreactive T cells
SG184907A1 (en) * 2010-04-28 2012-11-29 Oncoimmune Inc Methods of use of soluble cd24 for therapy of rheumatoid arthritis
EP2872218A4 (en) * 2012-07-13 2016-07-06 Univ Pennsylvania COMPOSITIONS AND METHODS FOR REGULATING T CAR LYMPHOCYTES
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
RU2741120C2 (ru) 2014-07-21 2021-01-22 Новартис Аг Лечение рака с использованием химерного антигенного рецептора cll-1
MX2017001011A (es) 2014-07-21 2018-05-28 Novartis Ag Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
AU2015343048A1 (en) * 2014-11-06 2017-05-18 Children's Research Institute, Children's National Medical Center Immunotherapeutics for cancer and autoimmune diseases
MX2017014095A (es) * 2015-05-07 2018-03-16 Oncoimmune Inc Uso de cd24 para disminuir los niveles de colesterol de las lipoproteinas de baja densidad.
US10639350B2 (en) 2015-08-10 2020-05-05 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center Methods and pharmaceutical compositions for improving wound healing using CD24
EP3411062B1 (en) * 2016-02-02 2020-11-25 Oncoimmune Inc. Use of cd24 proteins for treating leptin-deficient conditions
SG11201908077XA (en) * 2017-03-07 2019-09-27 Oncoimmune Inc Methods of use of soluble cd24 for treating systemic lupus erythematosus
TW201900671A (zh) * 2017-05-15 2019-01-01 美商昂科免疫公司 使用可溶性cd24進行神經保護及髓鞘再生的方法
CN112203725A (zh) 2018-06-13 2021-01-08 诺华股份有限公司 Bcma嵌合抗原受体及其用途

Also Published As

Publication number Publication date
CA2404340C (en) 2012-10-16
AU5979201A (en) 2001-10-08
CA2404340A1 (en) 2001-10-04
EP1267909A1 (en) 2003-01-02
EP1267909B1 (en) 2010-07-28
EP1267909A4 (en) 2006-05-03
WO2001072325A1 (en) 2001-10-04
ATE475428T1 (de) 2010-08-15
JP2004500110A (ja) 2004-01-08
DE60142684D1 (de) 2010-09-09
AU2001259792B2 (en) 2005-12-22
WO2001072325A9 (en) 2003-02-20

Similar Documents

Publication Publication Date Title
DK1267909T3 (da) Fremgangsmåder til blokering af vævsdestruktion ved autoreaktive T-celler
Brentjens et al. Interstitial immune complex nephritis in patients with systemic lupus erythematosus
KR100426113B1 (ko) 티(t)-세포항원,및티(t)-세포매개증상의진단및치료에있어서의이의용도
BR0008161A (pt) Uso de uma composição terapêutica para tratamento de uma célula tumoral, composição terapêutica, e kit para tratamento de uma célula tumoral
KR927003816A (ko) Cd3에 대한 항체
ATE458499T1 (de) Verbesserte abgabe von diagnostischen und therapeutischen stoffen an einem zielort
ES2180754T3 (es) Compuestos y metodos para la deteccion de infeccion por t. cruzi.
ATE330631T1 (de) Antikörperfragmente zur lokalen behandlung von augenerkrankungen
ES2293973T3 (es) Anticuerpos anti-ccr2 humanizados y metodos de uso de los mismos.
ATE506076T1 (de) Medizinische verwendung von anti-cs1 antikörpern
TR200200781T1 (tr) Birlikte uyaran bir sinyal transdüksiyon molekülü olan ailime karşı insan monoklonal antikoru ve bunun farmasötik kullanımı
DE69434725D1 (de) Zell- und Serumproteinanker und Konjugate
KR960706560A (ko) 인화 항체 및 이것의 사용 방법(humanized antibodies and uses thereof)
BG111719A (bg) Методи за прилагане на анти-tnf алфа антитела
ATE283289T1 (de) Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten
MX9705610A (es) Anticuerpos monoclonales especificos para diferentes epitopos de la gp39 humana y metodos para su uso en diagnostico y terapia.
Hansen et al. A mouse aminopeptidase N is a marker for antigen‐presenting cells and appears to be co‐expressed with major histocompatibility complex class II molecules
SE0103754L (sv) Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
BR9607171A (pt) Anticorpos monoclonais anti-cd6 e usos dos mesmos
DE68925226T2 (de) Monoklonale Antikörper
CN105744944A (zh) 免疫系统调节器
CN101679485B (zh) 骨桥蛋白的功能表位、针对该单位的单克隆抗体及它们的应用
ATE442439T1 (de) Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren
MXPA03011499A (es) Proteinas de fusion de fce para el tratamiento de alergia y asma.
DE69720241T2 (de) Ligand (tie ligand-4) vom tie-2 rezeptor und dessen verwendungen